rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Evolus, Inc.

EOLS · Nasdaq

Health CareBiotechnologyLeading

EOLS stood above a rising 150-day average in 10 of the last 52 weekly readings, including each of the last 9 weeks. It is 7.7% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
9 in a row
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$3.6M
Officials’ trades on record
0
Institutions holding
152 (+12)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 10 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 2
WhoDidSharesTraded
David MoatazediDirector, Officersold105,108at $9.042 Sep 2026filed 4 Sep 2026
David MoatazediDirector, Officersold13,669at $4.7520 Mar 2026filed 20 Mar 2026
Rui AvelarOfficersold3,119at $4.7520 Mar 2026filed 20 Mar 2026
Rui AvelarOfficersold29,996at $4.8917 Mar 2026filed 18 Mar 2026
David MoatazediDirector, Officersold116,720at $4.8917 Mar 2026filed 18 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders152+12 on the quarter
New · exited34 · 22
Reported value$336.7M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Nantahala Capital Management, LLCreduced · filed 14 Aug 20265,602,021$38.9M-774,836−12.2%
BlackRock, Inc.added · filed 7 Aug 20264,840,828$33.6M+550,445+12.8%
BRAIDWELL LPadded · filed 14 Aug 20263,155,209$21.9M+50,000+1.6%
Frazier Life Sciences Management, L.P.unchanged · filed 14 Aug 20262,630,665$18.3M00.0%
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20262,459,285$17.1M+1,172,423+91.1%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 20262,362,893$16.4M-107,515−4.4%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 20261,787,929$12.4M+326,770+22.4%
STATE STREET CORPadded · filed 7 Aug 20261,697,294$11.8M+376,504+28.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,608,394$11.2M+227,056+16.4%
Stonepine Capital Management, LLCreduced · filed 14 Aug 20261,590,162$11.0M-168,929−9.6%
31 Mar 2023 – 30 Jun 2026
101130158Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

David Moatazedi Company insiderDirector, Officer · last 2 Sep 20260 · 30
Rui Avelar Company insiderOfficer · last 20 Mar 20260 · 15
Albert G. White III Company insiderDirector · last 17 Feb 20261 · 0
Brady Stewart Company insiderDirector · last 17 Feb 20261 · 0
David N. Gill Company insiderDirector · last 17 Feb 20262 · 4
Karah Herdman Parschauer Company insiderDirector · last 17 Feb 20260 · 2
Tatjana Mitchell Company insiderChief Financial Officer · last 17 Feb 20260 · 0
Vikram Malik Company insiderDirector · last 17 Feb 20264 · 7
Tomoko Yamagishi-Dressler Company insiderChief Marketing Officer · last 22 Aug 20250 · 3
Sandra Beaver Company insiderChief Financial Officer · last 13 May 20250 · 9
Simone Blank Company insiderDirector · last 7 Mar 20253 · 0
Robert Hayman Company insiderDirector · last 7 Feb 20244 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202566.3%
Operating profit marginFY 2025 · to 31 Dec 2025-11.0%
Free cash flow marginFY 2025 · to 31 Dec 2025-15.4%
Return on capital employedFY 2025 · to 31 Dec 2025-21.7%
Share count trendFY 2025 · to 27 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$53.8M
Free cash flowFY 2025 · to 31 Dec 2025−$45.7M

Analyst forecasts

No analyst forecasts yet.